Liraglutide Anti-Diabetics yeRopa Shuga Kudzora CAS NO.204656-20-2
Product Detail
| CAS | 204656-20-2 | Molecular Formula | C172H265N43O51 |
| Molecular Weight | 3751.20 | Chitarisiko | Chena |
| Storage Condition | Chiedza chekudzivirira, 2-8 degree | Package | Aluminium foil bag / vial |
| Kuchena | ≥98% | Transportation | Cold Chain uye inotonhorera yekuchengetedza kuendesa |
Ingredients yeLiraglutide
Active Ingredient:
Liraglutide (analog yemunhu glucagon-like peptide-1 (GLP-1) inogadzirwa nembiriso kuburikidza neiyo genetic recombination tekinoroji).
Chemical Name:
Arg34Ls26-(N-e-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Zvimwe Ingredients:
Disodium Hydrogen Phosphate Dihydrate, Propylene Glycol, Hydrochloric Acid uye/kana Sodium Hydroxide (se pH Adjusters Chete), Phenol, uye Mvura Yejekiseni.
Application
Type 2 chirwere cheshuga
Liraglutide inovandudza kudzora kweglucose yeropa. Inoderedza kudya-kune hyperglycemia (kwemaawa makumi maviri nemana mushure mekutonga) nekuwedzera insulin secretion (chete) kana ichidiwa nekuwedzera mazinga eglucose, kunonoka kubuda kwegastric, uye kudzvinyirira prandial glucagon secretion.
Inokodzera varwere vane shuga yeropa ichiri kudzorwa zvisina kunaka mushure meiyo yakanyanya kutenderwa dosi ye metformin kana sulfonylureas chete. Inoshandiswa pamwe chete ne metformin kana sulfonylureas.
Inoshanda nenzira inoenderana neglucose, zvichireva kuti inokurudzira insulin secretion chete kana mazinga eglucose eropa akakwira kupfuura zvakajairika, kudzivirira "kupfuura". Nekuda kweizvozvo, inoratidza njodzi isingaite ye hypoglycemia.
Iyo ine mukana wekudzivisa apoptosis uye kukurudzira kuvandudzwa kwemasero e beta (anoonekwa muzvidzidzo zvemhuka).
Inoderedza kudya uye inhibits huremu hwemuviri, sezvakaratidzwa mumusoro-kune-musoro kudzidza maringe neglimepiride.
Pharmacological Action
Liraglutide ndeye GLP-1 analog ine 97% sequence homology kumunhu GLP-1, iyo inogona kusunga kune uye kumisa iyo GLP-1 receptor. Iyo GLP-1 receptor ndiyo inovavarira yekuzvarwa GLP-1, endogenous incretin hormone inosimudzira glucose-inotsamira insulin secretion kubva pancreatic β masero. Kusiyana neyakazvarwa GLP-1, iyo pharmacokinetic uye pharmacodynamic profiles yeliraglutide muvanhu inokodzera kamwe-zuva dosing regimen. Mushure mejojo ye subcutaneous, maitiro ayo ekuita kwenguva refu anosanganisira: kushamwaridzana kunononoka kutora; kusunga kune albumin; Yakakwira enzyme kugadzikana uye nekudaro yakareba plasma hafu yeupenyu.
Chiitiko che liraglutide chinopindirana nekudyidzana kwayo neGLP-1 receptor, zvichikonzera kuwedzera kwecyclic adenosine monophosphate (cAMP). Liraglutide inomutsa insulin secretion mune glucose-inotsamira nzira, uku ichidzikisa yakawandisa glucagon secretion nenzira inotsamira glucose.
Saka, kana glucose yeropa ichikwira, insulin secretion inokurudzirwa, nepo glucagon secretion inodzivirirwa. Kusiyana neizvi, liraglutide inoderedza insulin secretion panguva ye hypoglycemia pasina kukanganisa glucagon secretion. Iyo hypoglycemic mechanism ye liraglutide inosanganisirawo kuwedzera kudiki kwegastric yekubvisa nguva. Liraglutide inoderedza huremu hwemuviri uye huwandu hwemafuta emuviri nekudzikisa nzara uye simba rekudya.
